Davis S N, Vermeulen L, Banton J, Schwartz B S, Williams E C
Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison 53792, USA.
Am J Health Syst Pharm. 2000 Jun 1;57(11):1039-45. doi: 10.1093/ajhp/57.11.1039.
The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midline-catheter and central-venous-access device occlusions were studied. Reconstituted alteplase solution was stored at -70, -25, or 2 degrees C at concentrations of 0.5, 1, or 2 mg/mL. Durations of storage in the freezer were 0, 7, and 14 days, and durations of storage in the refrigerator were 0, 48, and 72 hours and 7 and 14 days. Samples were also assayed and cultured without prior freezing after refrigeration at 2 degrees C for 0, 48, and 72 hours and 7, 14, and 28 days. Fifty-eight pediatric and adult patients were enrolled in a separate study in which catheter clearance was initiated with alteplase 0.5 mg, and the dose was escalated to 1 and 2 mg sequentially until the catheter was cleared. The primary endpoint was restoration of catheter patency, and the secondary endpoint was the occurrence of bleeding episodes within 24 hours of alteplase administration. Catheter removal due to failure to restore patency was also documented. The activity and sterility of alteplase were maintained under all conditions studied. Fifty catheters (86.2%) were cleared with alteplase 0.5 mg, 5 (8.6%) after dose escalation to 1 mg, and 1 (1.7%) after escalation to 2 mg. The alteplase solution did not clear the occlusion in 2 catheters (3.4%): 1 had a mechanical obstruction and 1 cleared two hours after the 1-mg dose was deemed a failure. None of the six catheter removals was due to recalcitrant clots. Bleeding observed was not considered to be the result of alteplase administration. For use in clearing occlusions of venous-access devices, alteplase 0.5, 1, and 2 mg/mL retained sufficient fibrinolytic activity when stored for up to 14 days at 2 degrees C (28 days for the 0.5-mg/mL dilution) and when stored for 14 days at -70 or -25 degrees C followed by up to 14 days at 2 degrees C. The dose-escalation protocol was effective.
研究了重组阿替普酶溶液的活性和无菌性,以及阿替普酶剂量递增方案清除中线导管和中心静脉通路装置堵塞的有效性。重组阿替普酶溶液分别以0.5、1或2mg/mL的浓度储存在-70℃、-25℃或2℃。在冷冻条件下的储存时间为0、7和14天,在冷藏条件下的储存时间为0、48和72小时以及7和14天。样品在2℃冷藏0、48和72小时以及7、14和28天后,未经预先冷冻也进行了检测和培养。58名儿科和成年患者参与了另一项研究,该研究中导管清除从0.5mg阿替普酶开始,剂量依次递增至1mg和2mg,直至导管通畅。主要终点是导管恢复通畅,次要终点是阿替普酶给药后24小时内出血事件的发生。还记录了因未能恢复通畅而拔除导管的情况。在所有研究条件下,阿替普酶的活性和无菌性均得以维持。50根导管(86.2%)用0.5mg阿替普酶清除,5根(8.6%)在剂量递增至1mg后清除,1根(1.7%)在递增至2mg后清除。阿替普酶溶液未能清除2根导管(3.4%)中的堵塞:1根有机械性阻塞,1根在1mg剂量被判定无效两小时后通畅。6次导管拔除均非因顽固血栓所致。观察到的出血不被认为是阿替普酶给药的结果。用于清除静脉通路装置堵塞时,0.5、1和2mg/mL的阿替普酶在2℃储存长达14天(0.5mg/mL稀释液为28天)以及在-70℃或-25℃储存14天然后在2℃储存长达14天时,均保留了足够的纤溶活性。剂量递增方案是有效的。